1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
171.18 USD   -0.37%
08/11INSIDER SELL : Moderna
MT
08/11Moderna, Inc. CEO Stéphane Bancel, Goldman Sachs Chairman and CEO David Solomon, U.S. Senator John Hickenlooper, Among 2022 Mentors for Jeff Ubben Posse Fellows Program
AQ
08/11Moderna says vaccine facility in Montreal suburb could be operational by end of 2024
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, Moderna to be ready with BA.1-specific COVID boosters

06/28/2022 | 04:02pm EDT

June 28 (Reuters) - Pfizer Inc and Moderna Inc said on Tuesday they will be ready with COVID-19 vaccines designed to combat the BA.1 Omicron variant that was dominant last winter earlier than those designed to target currently dominant subvariants.

Moderna said it would be ready with a "couple of hundred million" of bivalent vaccines designed to combat BA.1 by September, but it would be late October or early November if the vaccine maker needed to design a vaccine to combat the currently dominant BA.4 and BA.5 subvariants.

Pfizer said it has a significant amount of BA.1 vaccine produced already and is preparing to produce a large amount of vaccine against BA.4 and BA.5 subvariants. It said either vaccine could be ready for an early October rollout. (Reporting by Leroy Leo in Bengaluru; Editing by Leslie Adler)


© Reuters 2022
All news about MODERNA, INC.
08/11INSIDER SELL : Moderna
MT
08/11Moderna, Inc. CEO Stéphane Bancel, Goldman Sachs Chairman and CEO David Solomon, U.S. S..
AQ
08/11Moderna says vaccine facility in Montreal suburb could be operational by end of 2024
AQ
08/10EUROPA-COVID-19 VACCINES : Commission and Moderna adapt delivery schedules for late summer..
AQ
08/09Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
RE
08/09European Commission, Moderna Map Out COVID-19 Vaccine Rollout for Autumn, Summer
MT
08/09Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
RE
08/09MODERNA : And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omic..
PU
08/09Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omi..
EQ
08/09Moderna, Inc. and European Commission Amend Covid-19 Vaccine Agreement to Supply Omicro..
CI
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 21 892 M - -
Net income 2022 11 063 M - -
Net cash 2022 16 818 M - -
P/E ratio 2022 6,48x
Yield 2022 -
Capitalization 66 966 M 66 966 M -
EV / Sales 2022 2,29x
EV / Sales 2023 4,58x
Nbr of Employees 2 700
Free-Float 90,4%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 171,18 $
Average target price 214,00 $
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068
CELLTRION, INC.5.05%21 967